Xenon Pharmaceuticals
XENE
81 hedge funds and large institutions have $431M invested in Xenon Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 8 closing their positions.
40% more capital invested
Capital invested by funds: $308M → $431M (+$123M)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
1% more funds holding
Funds holding: 80 → 81 (+1)
0.25% more ownership
Funds ownership: 79.79% → 80.04% (+0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$4.39M |
| 2 |
BlackRock
New York
|
+$4.1M |
| 3 |
Millennium Management
New York
|
+$3.48M |
| 4 |
Bank of New York Mellon
New York
|
+$2.37M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$910K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$6.64M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.85M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.81M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.57M |
| 5 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$1.67M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
76
Penserra Capital Management
Orinda,
California
| $12K | +$9.42K | +805 | New |
|
|
CHA
77
Carmichael Hill & Associates
Gaithersburg,
Maryland
| $1K | +$468 | +40 | +160% |
|
78
JP Morgan Chase
New York
| $1K | +$679 | +58 | New |
|
79
Daiwa Securities Group
Tokyo,
Japan
| $1K | +$772 | +66 | New |
|
80
Barclays
London,
United Kingdom
| $1K | +$1.01K | +86 | New |
|
|
BC
81
Boxer Capital
San Diego,
California
| – | -$6.64M | -600,000 | Closed |
|
|
AS
82
Altshuler Shaham
Tel Aviv,
Israel
| – | -$1.67M | -151,235 | Closed |
|
|
HS
83
HighVista Strategies
Boston,
Massachusetts
| – | -$482K | -43,517 | Closed |
|
84
Marshall Wace
London,
United Kingdom
| – | -$413K | -37,345 | Closed |
|
|
MWNA
85
Marshall Wace North America
New York
| – | -$272K | -24,531 | Closed |
|
|
CG
86
Cutler Group
San Francisco,
California
| – | -$9.36K | -800 | Closed |
|
87
Lazard Asset Management
New York
| – | -$7K | -705 | Closed |
|
88
BNP Paribas Financial Markets
Paris,
France
| – | -$1.05K | -95 | Closed |
|
XENE Hedge Fund Activity: Q4 2020 in Review
81 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2020, worth a combined $431M — up 40% from $308M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new XENE positions and 8 closed out — a net gain of 2 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was Ghost Tree Capital, adding an estimated $4.39M. The largest seller was Boxer Capital, exiting entirely with an estimated $6.64M sold.
- 81 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2020, up from 80 in Q3 2020.
- Funds reported $431M of Xenon Pharmaceuticals stock for Q4 2020, up 40% quarter-over-quarter.
- 10 funds opened new Xenon Pharmaceuticals positions in Q4 2020 and 8 closed out, a net change of +2 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2020 was Ghost Tree Capital, an estimated $4.39M added.
- The largest Xenon Pharmaceuticals seller in Q4 2020 was Boxer Capital, an estimated $6.64M sold.
Based on aggregated 13F filings for Q4 2020.